Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis

Epelbaum Jacques, Bedjaoui Nawel, Dardennes Roland, Feng Dan Dan, Gardette Robert. Grouselle Dominique, Loudes Catherine, Simon Axelle, Tolle Virginie, Yang Seung Kwon, Zizzari Philippe

► To cite this version:

Epelbaum Jacques, Bedjaoui Nawel, Dardennes Roland, Feng Dan Dan, Gardette Robert. Grouselle Dominique, et al.. Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. *Molecular and Cellular Endocrinology*, 2009, 314 (2), pp.244. 10.1016/j.mce.2009.08.026 . hal-00547655

HAL Id: hal-00547655

<https://hal.science/hal-00547655>

Submitted on 17 Dec 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis

Authors: Epelbaum Jacques, Bedjaoui Nawel, Dardennes Roland, Feng Dan Dan, Gardette Robert. Grouselle Dominique, Loudes Catherine, Simon Axelle, Tolle Virginie, Yang Seung Kwon, Zizzari Philippe

PII: S0303-7207(09)00457-2
DOI: doi:10.1016/j.mce.2009.08.026
Reference: MCE 7304

To appear in: *Molecular and Cellular Endocrinology*

Received date: 27-4-2009
Accepted date: 30-8-2009

Please cite this article as: Jacques, E., Nawel, B., Roland, D., Dan, F.D., Dominique, G.Rt.G., Catherine, L., Axelle, S., Virginie, T., Kwon, Y.S., Philippe, Z., Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis, *Molecular and Cellular Endocrinology* (2008), doi:10.1016/j.mce.2009.08.026

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Ghrelin/Obestatin: 2 antagonistic peptides arising from the same prohormone

Preproghrelin/obestatin

117 AA

gastro-intestinal tract

1 MLSSGTICSLLLL SMLWMDMAMA **GSSFLSPEHQKAQQRKESKKPPAKLQPR** ALEGWLH
 PEDRGQAEETEEE **L/MEI** **RFNAPFDVGILSGA** **Q/L** YQQHGRAL GKFLQDILWEEVKEAPADK 117

Ghrelin

↑ GH, Food Intake & Motility

Obestatin

↓ GH, Food Intake & Motility

Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis.

Epelbaum Jacques, Bedjaoui Nawel, Dardennes Roland, Feng Dan Dan, Gardette Robert. Grouselle Dominique, Loudes Catherine, Simon Axelle, Tolle Virginie, Yang Seung Kwon, Zizzari Philippe.

Centre de Psychiatrie & Neurosciences, UMR 894 Inserm; Faculté de Médecine, Université Paris Descartes; 2 ter rue d'Alésia, 75014 Paris France; tel: 331 (0) 40 78 92 82; fax: 331 (0) 45 80 72 93; e-mail: jacques.epelbaum@inserm.fr

Corresponding author : J. Epelbaum at the above address

Keywords : ghrelin, obestatin, GHSR1, GPR39, eating disorders

Abstract

Ghrelin and obestatin are two peptides isolated from the gastrointestinal tract and encoded by the same preproghrelin gene. They convey to the central nervous system informations concerning the nutritional status and/or the energy stores. Ghrelin, mostly acting through the GH-secretagogue receptor GH-SR, is a potent GH secretagogue, an orexigenic peptide and a long-term regulator of energy homeostasis. Obestatin was initially described for its anorexigenic effects and its binding to the G protein-coupled receptor 39 (GPR39). However, the role of obestatin is still controversial and the nature of the obestatin receptor remains an open question. This review is focussed on the possible implication of the ghrelin/obestatin system in psychiatric diseases with particular emphasis on eating disorders.

Ghrelin (Kojima et al., 1999) and obestatin (Zhang et al, 2005) are two peptides isolated from the gastrointestinal tract and encoded by the same preproghrelin gene. They convey to the central nervous system informations concerning the nutritional status and/or the energy stores. Ghrelin is a 28 amino-acid peptide which is acylated on the third amino-acid serine by the enzyme GOAT (Ghrelin-O-AcylTransferase) (Yang et al, 2008). It was initially characterized as the endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R) (Howard et al, 1996). However, ghrelin also regulates other neuroendocrine and metabolic functions in rodents and humans: it is a potent GH secretagogue, an orexigenic peptide and a long-term regulator of energy homeostasis (Bluet-Pajot et al, 2005). Obestatin is a 23 amino-acid peptide initially described for its anorexigenic effects and its binding to G protein-coupled receptor 39 (GPR39) (Zhang et al, 2005). However, the role of obestatin is still controversial and the nature of the obestatin receptor remains an open question.

GPR39 was originally cloned in 1997 (McKee et al, 1997) along with GPR38, later on identified as the motilin receptor (Feighner et al, 1999), as two novel orphan seven-transmembrane G protein-coupled receptors showing high structural similarity to the GH secretagogue receptor. After the claim that obestatin was an endogenous ligand for GPR39, at least four different groups reported that they could not elicit any binding of obestatin to GPR39 or any stimulatory function of the obestatin peptide on GPR39 (Chartrel et al, 2007; Holst et al, 2007; Lauwers et al, 2006; Tremblay et al, 2007). Thus, it was generally agreed that GPR39 is a receptor for Zn^{2+} (Holst et al, 2006; Yasuda et al, 2007) but not the receptor for obestatin (Zhang et al, 2007). Moreover, it was reported that if full length GPR39-1a is expressed selectively throughout the gastrointestinal tract, it is not expressed in the CNS, in contrast to a truncated splice variant five-transmembrane form, GPR39-1b, and an antisense gene called LYPD1 (Ly-6/PLAUR domain containing 1) which may encode a secreted protein product (Eggerod et al, 2007). On the other hand, immunofluorescent labeling of GPR39 was recently observed as punctuate staining near dendrites and at the periphery of cells expressing the neuronal nuclear marker (NeuN) in the CA3 region of the rat hippocampus (Besser et al, 2009) and obestatin induces the association of GPR39/beta-arrestin 1/Src signalling complex resulting in the transactivation of the epidermal growth factor receptor (EGFR) and downstream Akt signalling (Alvarez et al, 2009).

Even if GPR39 is not its *bona fide* receptor moiety, radiolabeled obestatin can bind in a specific and saturable manner with a subnanomolar affinity on HIT-T15 and INS-1E beta-cell membranes (Granata et al, 2008). At higher doses (10-100 M), it can also inhibit ^{125}I - glucagon-like peptide-1 and ^{125}I -Tyr4-acylated ghrelin binding to β -cell membranes. In the same cellular models, obestatin exerts proliferative, survival, and antiapoptotic effects under serum-deprived conditions and interferon- γ /tumor necrosis factor- α /interleukin- 1β treatment, particularly at pharmacological concentrations. Obestatin also mediates proliferation of human retinal pigment epithelial cells by MEK/ERK 1/2 Phosphorylation in a dose-dependent manner (Camna et al, 2007).

As for the demonstration of the nature of its receptors, obestatin physiological effects appear difficult to reproduce. Indeed, a very comprehensive study could not observe any effect of obestatin, injected either peripherally or centrally, on food intake, body weight, body composition, energy expenditure,

locomotor activity, respiratory quotient, basal of ghrelin-stimulated GH secretion or the expression of hypothalamic neuropeptides involved in energy balance regulation (Nogueiras et al, 2007). Similarly, central obestatin administration did not modify either spontaneous or ghrelin-induced food intake in both ad libitum and food restricted rats (Seoane et al, 2006) and neither intravenous nor intracerebroventricular administration of obestatin affected the secretion of basal GH, PRL, TSH and ACTH secretion nor ghrelin- or GHRH-induced GH secretion in rats (Yamamoto et al, 2007).

On the other hand, obestatin effectively blunted the hunger caused by short-term starvation in young-adult male rats and it inhibited feeding but did not modulate basal or hexarelin-stimulated GH and spontaneous corticosterone secretion in 10-days-old rats (Breciani et al, 2006). In mice, acute administration of obestatin (10-100 nmol/kg i.p) inhibited feeding and similar effects were observed in lean and fatty Zucker rats (Lagaud et al, 2007). Interestingly, dose-response relationships were U-shaped such that both low and high doses were without effect in either species. A similar U-shaped dose response was also observed on gut motility: at subnanomolar doses, obestatin (0.1-1 nM) reduced by half the ability of ghrelin (1 μ M) to facilitate electrical field stimulation-evoked contractions of the stomach (Bassil et al, 2007). However, at higher concentrations (10-1000 nM), changes were not statistically significant. Such peculiar dose-responses may explain the difficulties in reproducing the effects of obestatin as reported in the literature.

We recently confirmed that obestatin inhibits exogenous ghrelin actions on food intake and demonstrated that it also antagonizes its actions on GH secretion (Zizzari et al. 2007). To determine how plasma ghrelin/obestatin ratio is correlated to GH secretion and food intake, we developed sensitive immunoassays to measure ghrelin and obestatin pulsatile secretions in freely behaving rats and mice. Whereas fasting resulted in elevated ghrelin levels, obestatin levels were significantly reduced, suggesting that both hormones may be differentially regulated. Obestatin administration per se did not modify food intake. However, it inhibited ghrelin orexigenic effect that were evident in fed but not in fasted mice. The relationship between acylated ghrelin, obestatin, and GH secretions was evaluated by iterative blood sampling every 20 min during 6 h in freely moving adult male rats. Plasma obestatin levels exhibited an ultradian pulsatility with a frequency slightly lower than acylated ghrelin and GH but ghrelin and obestatin levels were not strictly correlated. Obestatin administration inhibited ghrelin stimulation of GH levels in freely moving rats. However, it was ineffective when GH release was monitored in superfused pituitary explants. It was therefore of interest to assess peptide interactions at the hypothalamic levels, taking advantage of a GHRH-GFP mouse model. Patch-clamp recordings in slices from mediobasal hypothalamus GFP transgenic mice indicated that ghrelin clearly decreased GABAergic transmission in 44% of recorded neurons (n=84) but did not affect glutamatergic transmission. Obestatin had no effect on glutamatergic or GABAergic synaptic transmission but it blocked ghrelin-induced decrease of GABA responses. Therefore, the balance between endogenous ghrelin and obestatin appears essential to maintain a homeostatic state of these neuroendocrine systems.

Interactions between ghrelin and obestatin may be relevant in term of eating disorders such as anorexia nervosa which affects 0.3 % of young girls with a mortality of 6 % per decade and is strongly familial with genetic factors (Hoek, 2006; Sullivan, 1995). The peak age of onset is between 15 and 19 yr old and the course of the disease is often marked by crossover to bulimia nervosa, mainly occurring within the first five years (Tozzi et al, 2005). Most studies on genetic factors focussed on the serotonin system but genes involved in the regulation of feeding and energy metabolism, including the ghrelin/obestatin system, are also good candidates (Ramos et al, 2007). Intravenous administration of ghrelin to healthy human subjects increases subjective appetite and energy intake (Wren et al, 2001). Circulating ghrelin levels are elevated in patients with anorexia nervosa and return to normal after weight gain (Otto et al, 2001; Tolle et al, 2003) but binge-eating/purging patients remain higher than restricting ones (Tanaka et al, 2004).

Family trios study of the three preproghrelin sequence single nucleotide were performed in 114 probands with anorexia nervosa and both their parents recruited in two specialized French centers (Dardennes et al, 2007). A transmission disequilibrium was observed for the Met 72 SNP of the preproghrelin gene. When stratified by clinical subtype, this polymorphism was preferentially transmitted for the trios with a bingeing/purging proband. An excess of transmission of the Gln90Leu72 preproghrelin/obestatin haplotype in patients with anorexia nervosa was also observed. The Leu72Met association was also observed in case control studies in Japanese women and with the 3056 T->C SNP in the non coding region in intron 2 of the *Ghr* gene (Ando et al, 2006; 2007). The latter one was significantly associated with a higher acylated ghrelin concentration, body weight, body mass index, fat mass, waist circumference, and skinfold thickness and a lower HDL-cholesterol concentration. Interestingly, the 3056C allele was related to elevated scores in the Drive for Thinness–Body Dissatisfaction subscale of the Eating Disorder Inventory -2. In a large European cohort composed of family trios and case-control comparisons, no significant association were detected for the three SNPs in the preproghrelin coding sequence (Cellini et al, 2006). Nevertheless, a preferential transmission of the Glu90leu72Arg51 haplotype was observed in bulimic offsprings, suggesting a possible involvement of this allelic combination in the aetiology of this particular form of the disease.

In an elegant study on 8 out patients (6 binge-purging and two restrictive AN) compared to 8 healthy control subjects, responses of circulating ghrelin and obestatin to sham feeding were markedly impaired in the patients. Ghrelin was highly stimulated while obestatin was parallely decreased (Monteleone et al, 2008a). However, olanzapine treatment which induces weight gain in experimental animals and humans, did not elicit a further increase in BMI in AN patients subserving a 3 months course of cognitive-behavioral psychotherapy and programmed nutritional rehabilitation (Brambilla et al, 2007). The same group of investigators reported an increased ratio of total ghrelin over obestatin in AN patients (Monteleone et al, 2008b). In an other study (Germain et al, 2009), the circadian profiles of obestatin, total and acylated ghrelin levels were different in constitutional thinness (CT) subjects and AN patients, two categories of severely underweight subjects which differ only by an impaired behaviour in the latter case. Six-points circadian profiles of plasma obestatin, acylated ghrelin, total

ghrelin and other hormonal and nutritional parameters were evaluated in 10 CT, 15 restricting-type AN, 7 restored from AN and 9 control subjects. Obestatin circadian levels were significantly higher in AN while no difference was found between CT and control subjects. Acylated and total ghrelin were both increased in AN. Acylated ghrelin/obestatin and total ghrelin/obestatin were found decreased in AN compared to CT or C subjects. The percentage of acylated ghrelin was decreased in CT group. A decreased ghrelin/obestatin ratio found in AN might participate in the restraint in nutriment intake of these patients. In contrast, in CT a lower percentage of acylated over total ghrelin might be considered in the aetiology of this condition.

In summary, the present state-of-knowledge on obestatin and its cognate receptor is leaving many unanswered questions that deserve further considerations. This led some authors to propose to rename the peptide as ghrelin-associated peptide (GAP) (Gourcerol et al, 2007). Understanding how two endocrine mediators produced by the same precursor but with antagonistic actions can regulate the vital neuroendocrine functions controlling body composition and energy balance is nevertheless essential to characterize pathologies such as obesity and eating disorders. The impact of preproghrelin gene and GHS-R polymorphisms in these pathologies remains to be fully elucidated.

References

- Alvarez C, Lodeiro M, Theodoropoulou M, Camina J, Casanueva F, Pazos Y. Obestatin stimulates Akt signalling in gastric cancer cells through {beta}-arrestin-mediated epidermal growth factor receptor transactivation. *Endocr Relat Cancer*. 2009 Jan 19. [Epub ahead of print]
- Ando T, Komaki G, Naruo T, Okabe K, Takii M, Kawai K, Konjiki F, Takei M, Oka T, Takeuchi K, Masuda A, Ozaki N, Suematsu H, Denda K, Kurokawa N, Itakura K, Yamaguchi C, Kono M, Suzuki T, Nakai Y, Nishizono-Maher A, Koide M, Murakami K, Nagamine K, Tomita Y, Ookuma K, Tomita K, Tonai E, Ooshima A, Ishikawa T, Ichimaru Y. Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. *Am J Med Genet B Neuropsychiatr Genet*. 2006 Dec 5;141B(8):929-34.
- Ando T, Ichimaru Y, Konjiki F, Shoji M, Komaki G. Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. *Am J Clin Nutr*. 2007 Jul;86(1):25-32.
- Bassil AK, Häglund Y, Brown J, Rudholm T, Hellström PM, Näslund E, Lee K, Sanger GJ. Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. *Br J Pharmacol*. 2007 Jan;150(1):58-64.
- Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, Hershfinkel M. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. *J Neurosci*. 2009 Mar 4;29(9):2890-901.
- Bluet-Pajot MT, Tolle V, Zizzari P, Tomasetto C, Grouselle D, Epelbaum J. [Ghrelin: a striking example of neuroendocrine peptide pleiotropy] . *Med Sci (Paris)*. 2005 Aug-Sep;21(8-9):715-21.
- Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? *Psychoneuroendocrinology*. 2007 May;32(4):402-6.
- Bresciani E, Rapetti D, Donà F, Bulgarelli I, Tamiasso L, Locatelli V, Torsello A. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. *Endocrinol Invest*. 2006 Sep;29(8):RC16-8.
- Camiña JP, Campos JF, Caminos JE, Dieguez C, Casanueva FF. *J Cell Physiol*. 2007 Oct;213(1):187-200.
- Cellini E, Nacmias B, Brecelj-Anderluh M, Badía-Casanovas A, Bellodi L, Boni C, Di Bella D, Estivill X, Fernandez-Aranda F, Foulon C, Friedel S, Gabrovsek M, Gorwood P, Gratacos M, Guelfi J, Hebebrand J, Hinney A, Holliday J, Hu X, Karwautz A, Kipman A, Komel R, Rotella CM, Ribases M, Ricca V, Romo L, Tomori M, Treasure J, Wagner G, Collier DA, Sorbi S; EC Framework V 'Factors in Healthy Eating' consortium. Case-control and combined family trios analysis of three polymorphisms in the ghrelin gene in European patients with anorexia and bulimia nervosa. *Psychiatr Genet*. 2006 Apr;16(2):51-2.
- Chartrel N, Alvear-Perez R, Leprince J, Iturrioz X, Reaux-Le Goazigo A, Audinot V, Chomarat P, Coge F, Nosjean O, Rodriguez M, Galizzi JP, Boutin JA, Vaudry H, Llorens-Cortes C. Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". *Science*. 2007 Feb 9;315(5813):766.
- Dardennes RM, Zizzari P, Tolle V, Foulon C, Kipman A, Romo L, Iancu-Gontard D, Boni C, Sinet PM, Thérèse Bluet M, Estour B, Mouren MC, Guelfi JD, Rouillon F, Gorwood P, Epelbaum J. Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with Anorexia nervosa: association with subtype, body-mass index, severity and age of onset. *Psychoneuroendocrinology*. 2007 Feb;32(2):106-13.
- Egerod KL, Holst B, Petersen PS, Hansen JB, Mulder J, Hökfelt T, Schwartz TW. GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. *Mol Endocrinol*. 2007 Jul;21(7):1685-98.

Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, O'Neill G, Van der Ploeg LH, Evans J, Patchett AA, Smith RG, Howard AD Receptor for motilin identified in the human gastrointestinal system. *Science* 1999 284:2184–2188

Germain N, Galusca B, Grouselle D, Frere D, Tolle V, Zizzari P, Lang F, Epelbaum J, Estour B. Ghrelin/obestatin ratio in two populations with low bodyweight: Constitutional thinness and anorexia nervosa. *Psychoneuroendocrinology*. 2009 Apr;34(3):413-9.

Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? *Regul Pept*. 2007 Jun 7;141(1-3):1-7.

Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghè C, Volante M, Papotti M, Muccioli G, Ghigo E. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. *Diabetes*. 2008 Apr;57(4):967-79.

Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW GPR39 signaling is stimulated by zinc ions but not by obestatin. *Endocrinology* 2007 148:13–20.

Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. *Curr Opin Psychiatry*. 2006 Jul;19(4):389-94.

Howard AD, Feighner SD, Cully DF, Arena JP, Liberatore PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevich M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science* 273:974-977.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 402:656-660.

Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Obestatin reduces food intake and suppresses body weight gain in rodents. *Biochem Biophys Res Commun*. 2007 May 25;357(1):264-9.

Landgren S, Jerlhag E, Zetterberg H, Gonzalez-Quintela A, Campos J, Olofsson U, Nilsson S, Blennow K, Engel JA. Association of pro-ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass. *Alcohol Clin Exp Res*. 2008 Dec;32(12):2054-61.

Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W Obestatin does not activate orphan G protein-coupled receptor GPR39. *Biochem Biophys Res Commun* 2006 351:21–25.

McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van der Ploeg LH. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. *Genomics* 1997 46:426–434.

Miyasaka K, Hosoya H, Sekime A, Ohta M, Amono H, Matsushita S, Suzuki K, Higuchi S, Funakoshi A. Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population. *J Neural Transm*. 2006 Sep;113(9):1279-85.

Monteleone P, Tortorella A, Castaldo E, Di Filippo C, Maj M. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene with anorexia nervosa or bulimia nervosa. *Neurosci Lett*. 2006 May 8;398(3):325-7.

Monteleone P, Tortorella A, Castaldo E, Di Filippo C, Maj M. The Leu72Met polymorphism of the ghrelin gene is significantly associated with binge eating disorder. *Psychiatr Genet*. 2007 Feb;17(1):13-6.

Monteleone P, Serritella C, Martiadis V, Maj M. Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. *Biol Psychiatry*. 2008a Dec 1;64(11):1005-8.

Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M.. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. *J Clin Endocrinol Metab*. 2008b Nov;93(11):4418-21.

Nogueiras R, Pfluger P, Tovar S, Arnold M, Mitchell S, Morris A, Perez-Tilve D, Vázquez MJ, Wiedmer P, Castañeda TR, DiMarchi R, Tschöp M, Schurmann A, Joost HG, Williams LM, Langhans W, Diéguez C. Effects of obestatin on energy balance and growth hormone secretion in rodents *Endocrinology*. 2007 Jan;148(1):21-6.

Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschöp M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. *Eur J Endocrinol*. 2001 Nov;145(5):669-73.

Monteleone P, Serritella C, Martiadis V, Maj M. Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. *Biol Psychiatry*. 2008 Dec 1;64(11):1005-8.

Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M.. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. *J Clin Endocrinol Metab*. 2008b Nov;93(11):4418-21.

Ramoz N, Versini A, Gorwood P. Eating disorders: an overview of treatment responses and the potential impact of vulnerability genes and endophenotypes. *Expert Opin Pharmacother*. 2007 Sep;8(13):2029-44.

Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in in both ad libitum and food restricted rats. *J Endocrinol Invest*. 2006 Sep;29(8):RC13-5.

Sullivan PF. Mortality in anorexia nervosa. *Am J Psychiatry*. 1995 Jul;152(7):1073-4.

Tanaka M, Nakahara T, Kojima S, Nakano T, Muranaga T, Nagai N, Ueno H, Nakazato M, Nozoe S, Naruo T. Effect of nutritional rehabilitation on circulating ghrelin and growth hormone levels in patients with anorexia nervosa. *Regul Pept*. 2004 Nov 15;122(3):163-8.

Tolle V, Kadem M, Bluet-Pajot MT, Frere D, Foulon C, Bossu C, Dardennes R, Mounier C, Zizzari P, Lang F, Epelbaum J, Estour B. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. *J Clin Endocrinol Metab*. 2003 Jan;88(1):109-16.

Tozzi F, Thornton LM, Klump KL, Fichter MM, Halmi KA, Kaplan AS, Strober M, Woodside DB, Crow S, Mitchell J, Rotondo A, Mauri M, Cassano G, Keel P, Plotnicov KH, Pollice C, Lilienfeld LR, Berrettini WH, Bulik CM, Kaye WH. Symptom fluctuation in eating disorders: correlates of diagnostic crossover. *Am J Psychiatry*. 2005 Apr;162(4):732-40.

Tremblay F, Perreault M, Klamman LD, Tobin JF, Smith E, Gimeno RE 2 Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. *Endocrinology* 2007 148:501–506.

Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. *J Clin Endocrinol Metab*. 2001 Dec;86(12):5992.

Yamamoto D, Ikeshita N, Daito R, Herningtyas EH, Toda K, Takahashi K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats Regul Pept. 2007 Feb 1;138(2-3):141-4.

Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008 Feb 8;132(3):387-96.

Yasuda S, Miyazaki T, Munechika K, Yamashita M, Ikeda Y, Kamizono A. Isolation of Zn²⁺ as an endogenous agonist of GPR39 from fetal bovine serum. J Recept Signal Transduct Res. 2007;27(4):235-46.

Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005 Nov 11;310(5750):996-9.

Zhang JV, Klein C, Ren P-G, Kass S, Ver Donck L, Moechars D, Hsueh AJW Response to comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake." Science 2007 315:766.

Zizzari P, Longchamps R, Epelbaum J, Bluet-Pajot MT (2007) Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 148:1648-1653.

Table 1 : Association of ghrelin and GHS-R1A gene polymorphisms with eating disorders and addictive phenotypes

References	Association Genotype/ phenotype
Ando et al. Am J Med Genet B Neuropsychiatr Genet. 2006;141(8):929-34	Leu72Met (408 C > A) and 3056 T > C polymorphisms of the preproghrelin gene associated with susceptibility to BN-P
Cellini et al. Psychiatr Genet. 2006 16(2):51-2	Glu90Leu72Arg51 haplotype possibly associated with susceptibility to BN-P
Monteleone et al. Neurosci Lett. 2006 398(3):325-7.	No association of the Arg51Gln and Leu72Met polymorphisms with AN or BN
Miyasaka et al, J Neural Transm. 2006;113(9): 1279-85.	CC type of GHSR gene polymorphism (171T/C) is a risk factor for BN, but not for AN
Monteleone et al. Psychiatr Genet 2007 17(1) :13-6	Leu72Met associated with binge eating disorder
Dardennes et al, 2007 Psychoneuroendocrinol. 32(2):106-13.	Leu72Met preferentially transmitted in AN-BP
Ando et al Am J Clin Nutr 2007 86 : 25-32	Weak negative correlation between BMI, insulin, HOMA and acyl- or desacylghrelin 3056C allele and Leu72MeT : significantly higher acylghrelin but not desacylghrelin with Leu72MeT. Drive to thinness and body dissatisfaction elevated in 3056C allele
Brambilla et al 2007 Psychoneuroendocrinol 2007 32:402-6	No difference with olanzapine treatment for BMI increase and ghrelin levels. In AN
Landgren et al Alcohol Clin Exp Res. 2008 32(12) :2054-61	Association of ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass.

AN : anorexia nervosa ; BN : bulimia nervosa ; BN-P : bulimia nervosa purging type

Figure legends

Figure1: The ghrelin/obestatin system

Ghrelin (green box) and obestatin (orange box) are cleaved from the same 117 aminoacid precursor. The three single nucleotide polymorphisms in the sequence of preproghrelin are indicated in red. Ghrelin stimulates GH secretion, appetite and gastric motility through the GHS-R receptor. Obestatin has been reported to decrease ghrelin-induced GH secretion, food intake and gut motility but these effects are not always observed and, despite initial claims that GPR 39, an orphan GPCR closely related to GHS-R was involved, the receptor of obestatin remains to be determined.